دورية أكاديمية
How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
| العنوان: | How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature |
|---|---|
| المؤلفون: | Martina Arcieri, Veronica Tius, Claudia Andreetta, Stefano Restaino, Anna Biasioli, Elena Poletto, Giuseppe Damante, Alfredo Ercoli, Lorenza Driul, Anna Fagotti, Domenica Lorusso, Giovanni Scambia, Giuseppe Vizzielli |
| المصدر: | Frontiers in Oncology, Vol 14 (2024) |
| بيانات النشر: | Frontiers Media S.A., 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | ovarian cancer, homologous recombination deficiency, BRCA protein, BRCAness, HRD testing, PARP inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD) and such defect accounts for synthetic lethality mechanism of PARP inhibitors (PARP-i). Several clinical trials have shown how BRCA and HRD mutational status profoundly affect first line chemotherapy as well as response to maintenance therapy with PARP-i, hence Progression Free Survival and Overall Survival. Consequently, there is urgent need for the development of increasingly reliable HRD tests, overcoming present limitations, as they play a key role in the diagnostic and therapeutic process as well as have a prognostic and predictive value. In this review we offer an overview of the state of the art regarding the actual knowledge about BRCA and HRD mutational status, the rationale of PARPi use and HRD testing (current and in development assays) and their implications in clinical practice and in the treatment decision process, in order to optimize and choose the best tailored therapy in patients with ovarian cancer. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2234-943X 07893043 |
| العلاقة: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1335196/fullTest; https://doaj.org/toc/2234-943XTest |
| DOI: | 10.3389/fonc.2024.1335196 |
| الوصول الحر: | https://doaj.org/article/3d1bed078930434ca0103b78ab067442Test |
| رقم الانضمام: | edsdoj.3d1bed078930434ca0103b78ab067442 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.3d1bed078930434ca0103b78ab067442 1038 3 Academic Journal academicJournal 1037.92358398438 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.3d1bed078930434ca0103b78ab067442&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/3d1bed078930434ca0103b78ab067442 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=2234943X&ISBN=&volume=14&issue=&date=20240301&spage=&pages=&title=Frontiers in Oncology&atitle=How%20BRCA%20and%20homologous%20recombination%20deficiency%20change%20therapeutic%20strategies%20in%20ovarian%20cancer%3A%20a%20review%20of%20literature&id=DOI:10.3389/fonc.2024.1335196 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Martina+Arcieri%22">Martina Arcieri</searchLink><br /><searchLink fieldCode="AR" term="%22Veronica+Tius%22">Veronica Tius</searchLink><br /><searchLink fieldCode="AR" term="%22Claudia+Andreetta%22">Claudia Andreetta</searchLink><br /><searchLink fieldCode="AR" term="%22Stefano+Restaino%22">Stefano Restaino</searchLink><br /><searchLink fieldCode="AR" term="%22Anna+Biasioli%22">Anna Biasioli</searchLink><br /><searchLink fieldCode="AR" term="%22Elena+Poletto%22">Elena Poletto</searchLink><br /><searchLink fieldCode="AR" term="%22Giuseppe+Damante%22">Giuseppe Damante</searchLink><br /><searchLink fieldCode="AR" term="%22Alfredo+Ercoli%22">Alfredo Ercoli</searchLink><br /><searchLink fieldCode="AR" term="%22Lorenza+Driul%22">Lorenza Driul</searchLink><br /><searchLink fieldCode="AR" term="%22Anna+Fagotti%22">Anna Fagotti</searchLink><br /><searchLink fieldCode="AR" term="%22Domenica+Lorusso%22">Domenica Lorusso</searchLink><br /><searchLink fieldCode="AR" term="%22Giovanni+Scambia%22">Giovanni Scambia</searchLink><br /><searchLink fieldCode="AR" term="%22Giuseppe+Vizzielli%22">Giuseppe Vizzielli</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Frontiers in Oncology, Vol 14 (2024) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Frontiers Media S.A., 2024. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2024 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22ovarian+cancer%22">ovarian cancer</searchLink><br /><searchLink fieldCode="DE" term="%22homologous+recombination+deficiency%22">homologous recombination deficiency</searchLink><br /><searchLink fieldCode="DE" term="%22BRCA+protein%22">BRCA protein</searchLink><br /><searchLink fieldCode="DE" term="%22BRCAness%22">BRCAness</searchLink><br /><searchLink fieldCode="DE" term="%22HRD+testing%22">HRD testing</searchLink><br /><searchLink fieldCode="DE" term="%22PARP+inhibitors%22">PARP inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD) and such defect accounts for synthetic lethality mechanism of PARP inhibitors (PARP-i). Several clinical trials have shown how BRCA and HRD mutational status profoundly affect first line chemotherapy as well as response to maintenance therapy with PARP-i, hence Progression Free Survival and Overall Survival. Consequently, there is urgent need for the development of increasingly reliable HRD tests, overcoming present limitations, as they play a key role in the diagnostic and therapeutic process as well as have a prognostic and predictive value. In this review we offer an overview of the state of the art regarding the actual knowledge about BRCA and HRD mutational status, the rationale of PARPi use and HRD testing (current and in development assays) and their implications in clinical practice and in the treatment decision process, in order to optimize and choose the best tailored therapy in patients with ovarian cancer. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2234-943X<br />07893043 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://www.frontiersin.org/articles/10.3389/fonc.2024.1335196/full; https://doaj.org/toc/2234-943X ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.3389/fonc.2024.1335196 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/3d1bed078930434ca0103b78ab067442" linkWindow="_blank">https://doaj.org/article/3d1bed078930434ca0103b78ab067442</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.3d1bed078930434ca0103b78ab067442 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3389/fonc.2024.1335196
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => ovarian cancer
[Type] => general
)
[1] => Array
(
[SubjectFull] => homologous recombination deficiency
[Type] => general
)
[2] => Array
(
[SubjectFull] => BRCA protein
[Type] => general
)
[3] => Array
(
[SubjectFull] => BRCAness
[Type] => general
)
[4] => Array
(
[SubjectFull] => HRD testing
[Type] => general
)
[5] => Array
(
[SubjectFull] => PARP inhibitors
[Type] => general
)
[6] => Array
(
[SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens
[Type] => general
)
[7] => Array
(
[SubjectFull] => RC254-282
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Martina Arcieri
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Veronica Tius
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Claudia Andreetta
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Stefano Restaino
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Anna Biasioli
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Elena Poletto
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Giuseppe Damante
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alfredo Ercoli
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lorenza Driul
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Anna Fagotti
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Domenica Lorusso
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Giovanni Scambia
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Giuseppe Vizzielli
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 03
[Type] => published
[Y] => 2024
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 2234943X
)
[1] => Array
(
[Type] => issn-print
[Value] => 07893043
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 14
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Frontiers in Oncology
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |